HMA - Heads of Medicines Agencies
  • RSS
  • Sitemap
  • Login (HMA-DMS)
  • Contact
  • About HMA
  • Human Medicines
  • Veterinary Medicines
  • You are here:
  • Home
  • >About HMA
  • >Transparency
  • >Guideline for transparency
  • >Archive · Guideline and recommendations for transparency
  • Vision and mission
  • Structure
  • Working Groups
  • National Contacts
  • COVID-19
  • Combination products
  • Transparency
    • Guideline for transparency
      • Archive · Guideline and recommendations for transparency
  • Meetings
  • Medicines Approval system
  • Publications and reports
  • Recently Published

 

Guideline and recommendations for transparency


Recommendations for transparency

Release of information concerning new applications for marketing authorisation for medicinal products before and after the decision is made ​​MT | pdf
Requests for access to PSURs (Periodic Safety Update Reports) (November 2009) | pdf
Agenda for product related issues (November 2008) | pdf

The United Kingdom (UK) withdrew from the European Union (EU) on 31 January 2020 and is no longer an EU Member State. HMA and CMDh/v are in the process of making appropriate changes to this website. If the site still contains content that does not yet reflect the withdrawal of the UK from the EU, this is unintentional and will be addressed. In case you notice information that should be updated, please report this website link using the contact form.

  • Useful Links
  • Privacy Policy
  • Credits & Disclaimer
  • Contact
© Heads of Medicines Agencies - https://www.hma.eu/about-hma/transparency/guideline-for-transparency/archive-guideline-and-recommendations-for-transparency.html